Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

04/26/2012 | 04:54pm US/Eastern

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
React to this article
Latest news on GILEAD SCIENCES, INC.
05:44p GILEAD SCIENCES : to Release Second Quarter 2015 Financial Results on Tuesday, J..
05:38p GILEAD SCIENCES : Announces Phase 3 Results From the First Study to Evaluate Swi..
05:17p GILEAD SCIENCES : Patent Issued for Process for Preparing an A2A-Adenosine Recep..
04:28p Yelp, Twitter, Cytec, Gilead and CNH Industrial are big market movers
11:31a GILEAD SCIENCES : US stocks move higher in early trading; investors wait for Fed..
08:46aDJStocks Gain After Fed Statement
07/28DJExpress Scripts Raises Guidance as Earnings Top Views
07/28 GILEAD SCIENCES : beats Street 2Q forecasts on surge in sales, profit
07/28DJExpress Scripts Raises Guidance as Earnings Top Views
07/28DJGilead Sales Soar on Hepatitis Drugs
Advertisement
Chart
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials